Illustrative image – not actual.
Piramal Pharma is investing USD 32 million (an estimated Rs 233 crore) for expanding its Michigan facility in the US for development and manufacture of active pharmaceutical ingredients (API).
The investment through Piramal Pharma Solutions, its contract development and manufacturing organisation, is to keep pace with expected demand based on current forecasts including potential new opportunities.
The expansion enables the business to support customers’ immediate and long-term API needs, besides strengthening its presence in North America.
The expansion expects to be ready in 2022. The company is expected to add around 20 new people, bringing total headcount to more than 180 employees.
